Status:
COMPLETED
Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)
Lead Sponsor:
Columbia University
Collaborating Sponsors:
DexCom, Inc.
Conditions:
Diabetic Ketoacidosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research study is to investigate the use of continuous glucose monitoring (CGM) device DEXCOM G6 in non-critically patients treated for diabetic emergency such as diabetic ketoacid...
Detailed Description
During the height of the COVID-19 pandemic, the investigators launched a quality improvement project with the goal of treating non-critically ill DKA patients outside of ICU setting to reallocate ICU ...
Eligibility Criteria
Inclusion
- Age \>18 years
- AG\>20 mEq/L
- Bicarbonate \<15mEq/L
- Positive urine ketones or beta hydroxybutyrate \>0.3 mmol/L
Exclusion
- Hypotension (Blood Pressure below 80/60 mmHg)
- Requirement for pressor therapy
- Contraindication for utilizing Dexcom CGM
Key Trial Info
Start Date :
June 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT05439928
Start Date
June 7 2022
End Date
March 31 2023
Last Update
May 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Hospital/ Columbia University Irving Medical Center
New York, New York, United States, 10032